Drug Profile
ALT P7
Alternative Names: ALT-P7; HM2-drug conjugate; HM2-MMAE; Trastuzumab-drug conjugate - Alteogen/3SBioLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Alteogen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric cancer; HER2 positive breast cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Gastric-cancer in South Korea (IV)
- 28 Oct 2023 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Metastatic disease, Second-line therapy or greater) in South Korea (IV)
- 04 Oct 2022 ALT P7 is available for licensing as of 04 Oct 2022. http://www.alteogen.com/en/ (Alteogen website, October 2022)